• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝切除术后肝细胞癌早期和晚期肝内复发的危险因素。

Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.

作者信息

Imamura Hiroshi, Matsuyama Yutaka, Tanaka Eiji, Ohkubo Takao, Hasegawa Kiyoshi, Miyagawa Shinichi, Sugawara Yasuhiko, Minagawa Masami, Takayama Tadatoshi, Kawasaki Seiji, Makuuchi Masatoshi

机构信息

Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.

出版信息

J Hepatol. 2003 Feb;38(2):200-7. doi: 10.1016/s0168-8278(02)00360-4.

DOI:10.1016/s0168-8278(02)00360-4
PMID:12547409
Abstract

BACKGROUND/AIMS: We conducted a retrospective cohort study to investigate factors to early and late phase recurrence of hepatocellular carcinoma (HCC).

METHODS

The study population consisted of 249 patients including 157 with cirrhosis who underwent hepatectomy for HCC. The endpoint was time-to-recurrence. Using a Cox regression model, factors to early and late phase recurrences were investigated censoring recurrence-free patients at the 2-year time point and in patients without recurrence at 2 years.

RESULTS

Actuarial probability of overall recurrence at 1, 3, and 5 years were 0.301, 0.623, and 0.790, respectively, with a median follow-up of 624 days. Early recurrence was observed in 123 out of 249 patients; while late recurrence was found in 61 out of 113 patients. Factors to early recurrence were as follows: non-anatomical resection, presence of microscopic vascular invasion, and serum alpha-fetoprotein level >or=32 ng/ml. Those contributing to late phase recurrence were higher grade of hepatitis activity, multiple tumors, and gross tumor classification.

CONCLUSIONS

Variables associated with metastatic recurrence were factors to early phase recurrence; whereas those related with elevated carcinogenesis contributed to late phase recurrence, thus providing an epidemiological evidence that different mechanisms, i.e. metastasis and de novo, are involved in intrahepatic recurrence after hepatectomy for HCC.

摘要

背景/目的:我们进行了一项回顾性队列研究,以调查肝细胞癌(HCC)早期和晚期复发的因素。

方法

研究人群包括249例患者,其中157例肝硬化患者接受了HCC肝切除术。终点是复发时间。使用Cox回归模型,在2年时间点对无复发患者以及2年时未复发的患者进行审查,研究早期和晚期复发的因素。

结果

中位随访624天,1年、3年和5年的总复发精算概率分别为0.301、0.623和0.790。249例患者中有123例出现早期复发;而113例患者中有61例出现晚期复发。早期复发的因素如下:非解剖性切除、存在微小血管侵犯以及血清甲胎蛋白水平≥32 ng/ml。导致晚期复发的因素是更高的肝炎活动度、多发肿瘤和大体肿瘤分类。

结论

与转移复发相关的变量是早期复发的因素;而与致癌作用增强相关的变量导致晚期复发,从而提供了流行病学证据,表明不同机制,即转移和新发,参与了HCC肝切除术后的肝内复发

相似文献

1
Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.肝切除术后肝细胞癌早期和晚期肝内复发的危险因素。
J Hepatol. 2003 Feb;38(2):200-7. doi: 10.1016/s0168-8278(02)00360-4.
2
Risk factors, prognosis, and management of early and late intrahepatic recurrence after resection of primary clear cell carcinoma of the liver.原发性肝透明细胞癌切除术后早、晚期肝内复发的危险因素、预后及处理。
Ann Surg Oncol. 2011 Jul;18(7):1955-63. doi: 10.1245/s10434-010-1540-z. Epub 2011 Jan 15.
3
Risk factors and management for early and late intrahepatic recurrence of solitary hepatocellular carcinoma after curative resection.根治性切除术后孤立性肝细胞癌早期和晚期肝内复发的危险因素及管理
HPB (Oxford). 2015 May;17(5):422-7. doi: 10.1111/hpb.12367. Epub 2014 Nov 24.
4
Clinical analysis of the risk factors for recurrence of HCC and its relationship with HBV.肝癌复发危险因素的临床分析及其与乙肝病毒的关系
World J Gastroenterol. 2005 Apr 14;11(14):2061-6. doi: 10.3748/wjg.v11.i14.2061.
5
Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma.肝细胞癌切除术后早期和晚期肝内复发的不同危险因素及预后
Cancer. 2000 Aug 1;89(3):500-7.
6
Hepatitis B virus surface antigen-negative and hepatitis C virus antibody-negative hepatocellular carcinoma: clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence after resection.乙型肝炎病毒表面抗原阴性和丙型肝炎病毒抗体阴性肝细胞癌:切除术后早期和晚期肝内复发的临床特征、结局和危险因素。
Cancer. 2013 Jan 1;119(1):126-35. doi: 10.1002/cncr.27697. Epub 2012 Jun 26.
7
Effect of Background Liver Cirrhosis on Outcomes of Hepatectomy for Hepatocellular Carcinoma.背景性肝硬化对肝细胞癌肝切除术结局的影响。
JAMA Surg. 2017 Mar 15;152(3):e165059. doi: 10.1001/jamasurg.2016.5059.
8
Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes.肝细胞癌肝切除术后复发:危险因素、治疗及预后
Surgery. 2007 Mar;141(3):330-9. doi: 10.1016/j.surg.2006.06.028. Epub 2006 Nov 1.
9
Risk factors for early and late intrahepatic recurrence in patients with single hepatocellular carcinoma without macrovascular invasion after curative resection.根治性切除术后无大血管侵犯的单发肝细胞癌患者早期和晚期肝内复发的危险因素
Asian Pac J Cancer Prev. 2013;14(8):4759-63. doi: 10.7314/apjcp.2013.14.8.4759.
10
Recurrence of Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma After Hepatectomy.巴塞罗那临床肝癌分期A期肝细胞癌肝切除术后复发
Am J Med Sci. 2017 Sep;354(3):262-267. doi: 10.1016/j.amjms.2017.05.014. Epub 2017 May 25.

引用本文的文献

1
Secreted lumican from the tumor microenvironment potentiates HCC stemness and progression.肿瘤微环境中分泌的核心蛋白聚糖增强肝癌干细胞特性及进展。
Hepatol Commun. 2025 Aug 15;9(9). doi: 10.1097/HC9.0000000000000778. eCollection 2025 Sep 1.
2
G6PC1 expression as a prognostic biomarker associated with metabolic reprogramming and tumor microenvironment in hepatocellular carcinoma.G6PC1表达作为与肝细胞癌代谢重编程和肿瘤微环境相关的预后生物标志物。
Front Immunol. 2025 Aug 1;16:1623315. doi: 10.3389/fimmu.2025.1623315. eCollection 2025.
3
Postoperative hepatitis B virus reactivation and its impact on survival in HBV-related hepatocellular carcinoma patients undergoing conversion therapy with interventional therapy combined with tyrosine kinase inhibitors and immune checkpoint inhibitors.
接受介入治疗联合酪氨酸激酶抑制剂及免疫检查点抑制剂的转化治疗的乙肝相关肝细胞癌患者术后乙肝病毒再激活及其对生存的影响
Front Cell Infect Microbiol. 2025 Jul 17;15:1598193. doi: 10.3389/fcimb.2025.1598193. eCollection 2025.
4
Role of immune checkpoint inhibitor combinations in resectable and unresectable, embolization-eligible hepatocellular carcinoma.免疫检查点抑制剂联合疗法在可切除和不可切除、适合栓塞治疗的肝细胞癌中的作用
Ther Adv Med Oncol. 2025 Jul 24;17:17588359251357719. doi: 10.1177/17588359251357719. eCollection 2025.
5
Adjuvant HAIC combined with anlotinib and TQB2450 for resected high-risk hepatocellular carcinoma.辅助性肝动脉灌注化疗联合安罗替尼和TQB2450用于切除术后的高危肝细胞癌
Innovation (Camb). 2025 Apr 11;6(7):100910. doi: 10.1016/j.xinn.2025.100910. eCollection 2025 Jul 7.
6
Correlation of radiotherapy, targeted therapy, and immunotherapy with hepatocellular carcinoma recurrence.放射治疗、靶向治疗和免疫治疗与肝细胞癌复发的相关性
World J Gastrointest Oncol. 2025 Jul 15;17(7):107815. doi: 10.4251/wjgo.v17.i7.107815.
7
Survival impact and recurrence prediction using oncologic resectability classification in hepatocellular carcinoma following hepatic resection: a Japanese multi-center study.肝切除术后肝细胞癌的肿瘤可切除性分类对生存的影响及复发预测:一项日本多中心研究
Int J Clin Oncol. 2025 Jul 14. doi: 10.1007/s10147-025-02840-z.
8
Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.经动脉化疗栓塞联合酪氨酸激酶抑制剂治疗肝细胞癌的疗效:一项系统评价与Meta分析
Cancers (Basel). 2025 Jun 24;17(13):2110. doi: 10.3390/cancers17132110.
9
Gd-EOB-DTPA-enhanced MRI proves advantageous in selecting surgical candidates for patients with early-stage hepatocellular carcinoma: An analysis in terms of oncological outcomes.钆塞酸二钠增强磁共振成像在为早期肝细胞癌患者选择手术候选者方面具有优势:一项基于肿瘤学结局的分析。
ILIVER. 2024 Sep 18;3(4):100117. doi: 10.1016/j.iliver.2024.100117. eCollection 2024 Dec.
10
Nomogram prediction of overall survival in patients with bone metastases from hepatocellular carcinoma: a SEER-based retrospective cohort study.肝细胞癌骨转移患者总生存的列线图预测:一项基于监测、流行病学和最终结果(SEER)数据库的回顾性队列研究
Sci Rep. 2025 Jul 1;15(1):21767. doi: 10.1038/s41598-025-06665-8.